Literature DB >> 7511895

[D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P induces apoptosis in lung cancer cell lines in vitro.

J G Reeve1, N M Bleehen.   

Abstract

The broad spectrum antagonist [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P has been shown previously to inhibit the growth of small cell lung cancer cells both in vitro and in vivo. To elucidate further the pathways involved in the growth inhibitory actions of [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P we have examined the effect of this agent on cell viability and the induction of apoptosis in small cell and non-small cell lung cancer cells. Treatment of lung tumor cells with [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P caused a concentration-dependent loss of cell viability which was accompanied by the onset of apoptosis, as defined by cytological criteria and DNA fragmentation. This effect occurred in both small cell and non-small cell lung cancer cells and was not dependent on de novo protein synthesis. Such findings indicate that the antiproliferative action of [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P involves a signal transduction pathway for apoptosis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511895     DOI: 10.1006/bbrc.1994.1374

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  Association of genetic variants in tachykinins pathway genes with colorectal cancer risk.

Authors:  Yunxian Yu; Yifeng Pan; Mingjuan Jin; Mingwu Zhang; Shanchun Zhang; Qilong Li; Xia Jiang; Hui Liu; Jing Guo; He Liu; Kun Chen
Journal:  Int J Colorectal Dis       Date:  2012-06-26       Impact factor: 2.571

2.  Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis.

Authors:  D Singh; D D Joshi; M Hameed; J Qian; P Gascón; P B Maloof; A Mosenthal; P Rameshwar
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

Review 3.  Involvement of substance P and the NK-1 receptor in pancreatic cancer.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

4.  The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines.

Authors:  Miguel Muñoz; Ana González-Ortega; Rafael Coveñas
Journal:  Invest New Drugs       Date:  2010-12-01       Impact factor: 3.850

Review 5.  The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.

Authors:  Miguel Munoz; Rafael Covenas; Francisco Esteban; Maximino Redondo
Journal:  J Biosci       Date:  2015-06       Impact factor: 1.826

6.  Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism.

Authors:  Daniel Chan; Lajos Gera; John Stewart; Barbara Helfrich; Marileila Verella-Garcia; Gary Johnson; Anna Baron; Jie Yang; Theodore Puck; Paul Bunn
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-02       Impact factor: 11.205

7.  The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug.

Authors:  Miguel Muñoz; Marisa Rosso
Journal:  Invest New Drugs       Date:  2009-01-17       Impact factor: 3.850

8.  NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2.

Authors:  Miguel Muñoz; Marisa Rosso; Francisco J Aguilar; Miguel A González-Moles; Maximino Redondo; Francisco Esteban
Journal:  Invest New Drugs       Date:  2007-09-29       Impact factor: 3.850

Review 9.  Targeting NK-1 Receptors to Prevent and Treat Pancreatic Cancer: a New Therapeutic Approach.

Authors:  Miguel Muñoz; Rafael Coveñas
Journal:  Cancers (Basel)       Date:  2015-07-06       Impact factor: 6.639

10.  Metabolism of the broad-spectrum neuropeptide growth factor antagonist: [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P.

Authors:  D A Jones; J Cummings; S P Langdon; A J Maclellan; T Higgins; E Rozengurt; J F Smyth
Journal:  Br J Cancer       Date:  1996-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.